Status:
COMPLETED
Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection
Lead Sponsor:
Dhaka Medical College
Conditions:
Covid19
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
On 31 December 2019, the World Health Organization (WHO) was formally notified about a cluster of cases of pneumonia in Wuhan City, China. On 7 January the responsible virus was isolated and its genom...
Detailed Description
OBJECTIVES: General objectives: To observe the benefit (clinical and microbiological) of Ivermectin and Doxycycline in Confirmed Covid 19 cases. Specific objectives: 1. To observe the clinical out...
Eligibility Criteria
Inclusion
- COVID-19 infection, confirmed by polymerase chain reaction (PCR) test within 3 days from enrollment
- Only mild and moderate COVID-19 infected cases
- Able to provide informed consent
Exclusion
- Unable to take oral medication
- Pregnant or breast feeding lady
- Patients with severe COVID symptoms or admission in ICU/HDU
- Alanine Aminotransferase (ALT) or aspartate aminotransferase (AST) more than 5 upper limit of normal (ULN)
- On non-invasive positive pressure ventilation or mechanical ventilation at time of study entry
- Known hypersensitivity to Doxycycline or ivermectin or its components.
Key Trial Info
Start Date :
June 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 10 2020
Estimated Enrollment :
400 Patients enrolled
Trial Details
Trial ID
NCT04523831
Start Date
June 1 2020
End Date
September 10 2020
Last Update
October 9 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Dhaka Medical College
Dhaka, Bangladesh, 1000